Susceptibility of clinical isolates of Pseudomonas aeruginosa in the Northern Kyushu district of Japan to carbapenem antibiotics, determined by an integrated concentration method: Evaluation of the method based on Monte Carlo simulation

Journal of Infection and Chemotherapy

Volumn 14, Issue 3, 2008, Pages 238-243

  Nagasawa, Zenzo ^a   Kusaba, Koji ^a   Aoki, Yosuke ^a  

^a SAGA UNIVERSITY HOSPITAL   (Japan)

Author keywords

Carbapenem; Pharmacokinetics Pharmacodynamics (PK PD); Pseudomonas aeruginosa; Susceptibility

Indexed keywords

BIAPENEM; CARBAPENEM; DORIPENEM; IMIPENEM; MEROPENEM; PANIPENEM;

ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; CONTROLLED STUDY; DILUTION; JAPAN; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PSEUDOMONAS AERUGINOSA;

EID: 45749126071     PISSN: 1341321X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10156-008-0609-0     Document Type: Article

References (15)

1. Shimojima M. Results on sensitivity of 760 000 fresh clinical isolates to various antibacterial agents, collected from various prefectures Shinryou to Shinnyaku 2006;43:697-753.
2. National Committee for Clinical Laboratory Standards (NCCLS). Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard-sixth edition M7-A6. Wayne, PA: NCCLS: 2003.
3. National Committee for Clinical Laboratory Standards. MIC testing supplemental tables M100-S13. Wayne, PA: NCCLS; 2003.
4. Andes D, Craig WA. Animal model pharmacokinetics and pharmacodynamics: a critical review. Int J Antimicrob Agents 2002;19:261-268.
5. Kuti JL, Dandekar PK, Nightingale CH, Nicolau DP. Use of Monte Carlo simulation to design strategy for meropenem. J Clin Pharmacol 2003;43:1116-1123.
6. Mouton JW, Punt N, Vinks AA. A retrospective analysis using Monte Carlo simulation to evaluate recommended ceftazidime dosing regimens in healthy volunteers, patients with cystic fibrosis, and patients in the intensive care unit. Clin Ther 2005;27:762-772.
7. Nakagawa K, Koyama M, Hayase K, Kesado T. Imipenem, cilastatin sodium, imipenem/cilastatin sodium clinical phase I study. Jpn J Chemother 1985;33:357-378.
8. Saito R, Miura T, Tarao F, Saito K. Pharmacokinetic study on biapenem. Jpn J Chemother 1994;42:277-284.
9. Kuroda N, Munekage T, Yamano Y. Bactericidal activity of doripenem using in vitro pharmacodynamic models. Jpn J Chemother 2005;53:92-103.
10. Matsumoto H, Yokota K, Kobayashi H, editors. Thirty-ninth annual meeting of the Japanese Society of Chemotherapy. Tokyo: New drug symposium meropenem (SM-7338) booklet; 1991. p. 77-114.
11. Saito R, Shimada K, editors. Thirty-eighth annual meeting of the Western Chapter of the Japanese Society of Chemotherapy. Gihu: New drug symposium CS-976 booklet; 1990. p. 77-120.
12. Mikamo H. Optimizing meropenem therapy based on pharmacokinetics/ pharmacodynamics (PK/PD) for severe infection disease. Antibiot Chemother 2005;21:105-113.
13. Mikamo H, Totsuka K. The proper use of carbapenem examined by Monte Carlo simulation. Jpn J Chemother 2005;58:359-367.
14. Craig WA. The role of pharmacodynamics in effective treatment of community-acquired pathogens. Advanced Studies in Medicine 2002;2:126-133.
15. Ambrose PG, Owens RC, Garvey MJ, Jones RN. Pharmacodynamics considerations in the treatment of moderate to severe pseudomonal infections with cefepime. J Antimicrob Chemother 2002;49:445-453.